Objective:Toinvestigatetheimmunotherapyefficacyoffusioncells(dendritic-C6anti-TGF-β1cells)inthetreatmentofintracranialgliomas.Methods:Dendriticcellswereisolatedfromratbone-marrowprecursorsstimulatedinvitrowithgranulocyte-macrophagecolony-stimulatingfactor(GM-CSF)andInterleukin-4(IL-4).C6anti-TGF-β1cellsoriginallyfromC6celllineofaratglioblastomaweretransfectedwithplasmidofTGF-β1anti-sensegene.FusionsofdendriticcellsandC6anti-TGF-β1cellswerepreparedbypolyethyleneglycol(PEG).TheDC/C6anti-TGF-β1fusioncellswereobservedandconfirmedbylightmicroscopyandscanningelectronmicroscopy.Experimentalratswerepidedintothreegroupsatrandom:C6cells(I),dendritic-C6anti-TGF-β1fusioncellsandC6cells(II)andIMDMmediumonly(III).Thecellswereinjectedintorightparietalloberegionoftheratwithstereotaxictechnique.Histology,tumornecrosisandsurvivaltimewereevaluated.Results:ComparedwiththeratsthatreceivedC6cells(survivalmediantimewaslessthan20days,tumorregionwasseeninallfieldsofobserved),theratsinjectedwithdendritic-C6anti-TGF-β1fusioncellsandC6cellsgotamoreprolongedlifespan(morethan59days),aswellaslesstumorregion(5.01%-6.2%).Therewasnotumornecrosis,butsomegliaswereseeninsurroundings.Allratsweresurvivedandnonecrosiswasobservedinnegativecontrolgroup.StatisticalanalysisshowedthatgroupIIhadsignificantdifferencecomparedwithgroupI.Conclusions:Dendritic-C6anti-TGF-β1fusioncellscouldprolongthelifespanofrats,providingastrategytoachieveanantitumorresponseagainsttumorsinthecentralnervoussystem.
